Taysha's R&D Chief Sells $1.2 Million in Stock Amid Strong Share Performance
Nagendran Sukumar, president and head of R&D at Taysha Gene Therapies (NASDAQ:TSHA), sold 200,000 shares for $1.2 million under a Rule 10b5-1 trading plan on July 10, 2026. The stock has surged by 149% over the past year despite Taysha reporting significant losses.
Tickers: $TSHA
Topics: biotechnology executive stock sales gene therapy SEC filings